Free Trial
LON:CLIN

Clinigen Group (CLIN) Share Price, News & Analysis

Clinigen Group logo

About Clinigen Group Stock (LON:CLIN)

Key Stats

Today's Range
N/A
50-Day Range
925
925
52-Week Range
N/A
Volume
539,375 shs
Average Volume
1.83 million shs
Market Capitalization
£1.23 billion
P/E Ratio
64.69
Dividend Yield
0.82%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Clinigen Group plc operates as a pharmaceutical and services company in the United Kingdom, rest of Europe, the United States, South Africa, Australia, and internationally. It operates through Services and Products divisions. The company provides a set of niche and high value services to pharma and biotech clients prior to product launch. It also provides access to critical medicines around the world for patients with unmet needs. In addition, the company provides a portfolio of specialist medicines to service the needs of healthcare professionals and their patients in both licensed and unlicensed markets. Further, it offers Nortriptyline Colonis for the treatment of depressive disorder; Metformin Colonis for the treatment of type 2 diabetes mellitus; Magnesium Chewable Tablets, an oral magnesium supplements for the treatment of patients with chronic magnesium loss; Iloprost, a concentrate for solution for infusion; Glycopyrronium Bromide, an oral solution for the treatment of severe sialorrhoea; Acetylcysteine, an oral solution for the treatment of respiratory disorders associated with thick, viscous, and mucus hypersecretion; Cardioxane that protects the heart against the cardiotoxic effects of anthracyclines; Ethyol, which protect against the harmful effects of chemotherapy medications and radiation treatment; Proleukin for the treatment of kidney cancer; Imukin that is used in chronic granulomatous disease; Totect, a dexrazoxane product; Foscavir, an anti-virals that work by stopping viruses from multiplying in number; and Savene, which is indicated in adults for the treatment of anthracycline extravasation. The company was incorporated in 2008 and is headquartered in Burton-on-Trent, the United Kingdom.

Receive CLIN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Clinigen Group and its competitors with MarketBeat's FREE daily newsletter.

CLIN Stock News Headlines

Evotec Shares Jump After Triton Acquires Stake
Triton Weighs Takeover Deal for Drug Developer Evotec
Your chance to get on the next “60-Second Trade”
Ever heard of the “60-Second Trade”? It’s a unique cash flow strategy that lets regular traders target anywhere from $100 to a couple of thousand in extra cash flow in as little as 7 days… In on Monday, out on Friday!
See More Headlines

CLIN Stock Analysis - Frequently Asked Questions

Clinigen Group plc (LON:CLIN) issued its quarterly earnings results on Thursday, September, 17th. The company reported $65.60 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $63.50 by $2.10.

Shares of CLIN stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Clinigen Group investors own include Comerica (CMA), Honda Motor (HMC), Albemarle (ALB), Advanced Accelerator Applications (AAAP), First Hawaiian (FHB), General Electric (GE) and Landec (LNDC).

Company Calendar

Last Earnings
9/17/2020
Today
12/21/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Delivery
Sub-Industry
Trading
CIK
N/A
Fax
N/A
Employees
1,000
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£565.60 million
Book Value
GBX 341.90 per share

Miscellaneous

Free Float
N/A
Market Cap
£1.23 billion
Optionable
Not Optionable
Beta
N/A
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

This page (LON:CLIN) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners